Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Polyrizon has completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker study, marking a key step toward patient enrollment. The planned first-in-human trial will enroll up to 120 patients with seasonal allergic rhinitis, randomized to receive either NASARIX™ or a saline control.
Key figures
- Clinical sites
- 5
- Planned patients
- 120
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.